News Article | May 8, 2017
For the first time eye researchers have been able to reduce the time it takes for older eyes to adapt to the dark with use of an oral nutraceutical (Longevinex). Prolonged dark adaptation time is a marker of the future onset of a dreaded vision problem - macular degeneration. Twelve of the first fourteen consecutive eyes tested improved or were unexpectedly stable after a dark adaptation test was administered among senior adults with pre-existing visual loss taking a selected daily oral nutraceutical. While only a small number of eyes were tested the effect was statistically so demonstrable there is only ~1% probability the results obtained from this intervention were obtained by chance (p value 0.01). [Statistics How To] Dr. Stuart Richer OD, PhD, Director, Ocular Preventive Medicine at the Captain James A Lovell Federal Health Care Facility, North Chicago, IL, and President of the Ocular Nutrition Society, announced the discovery at the annual meeting of the Association for Research in Vision & Ophthalmology (ARVO), Baltimore, MD, May 8, 2017. Macular degeneration affects millions of senior adults. There is no proven remedy for this insidious sight-robbing disease. The fact a nutraceutical has been demonstrated for the first time to reverse a predictive measure for macular degeneration is a monumental development in preventive medicine says Dr. Richer. All eyes tested were among subjects who already had a diagnosed case of dry age-related macular degeneration (AMD) and whose vision had not improved with the use of the Age Related Eye Disease (AREDs) antioxidant supplement formulated by the National Eye Institute. "However, the greater application of this dark adaptation vision test is among family members of individuals who have been diagnosed with macular degeneration since prolonged dark adaptation time can predict future onset of this dreaded eye disease 4 years before it can be clinically diagnosed. Forty-five percent (45%) of the population who have a parent with macular degeneration will develop the disease in their lifetimes," says lead researcher Stuart Richer OD, PhD. "If this continues to be demonstrated in larger groups, we just may have, for the first time, a preventive for the most common cause of visual decline in senior Americans," says Dr. Stuart Richer. The dark adaptation test (Adapt Dx by Maculogix), an FDA-approved medical device that has been 10 years in the making, utilizes a blast of light to bleach visual chemicals (rhodopsin, pronounced row-dop-sin) from the back of the eyes and then times how long it takes for these chemicals to be replenished. A prolonged dark adaption time occurs long prior to detection of any observable signs of disease or decline in vision. In an individual with perfect 20/20 vision and no other signs of eye disease, over 6.5 minutes to adapt to the dark is predictive of future loss of sight by up to 4 years. [Investigative Ophthalmology Vision Science April 2016] A published study of over 380 adults with nearly perfect 20/20 vision, 60-89 years of age, found 78% had normal dark adaptation time and 22% required prolonged time to adapt to dark conditions. Aside from age (older) and sex (female), regular use of alcohol was the greatest modifiable risk factor associated with prolonged dark adaptation. [Investigative Ophthalmology & Visual Sciences May 2014] There are ~48 million Americans over the age of 65 and if the above figures translate to the entire population (22% of ~50 million), dark adaptation testing could uncover ~11 million senior Americans with near-perfect visual acuity who will develop macular degeneration in their near future. According to the Bright Focus Foundation there are ~11 million Americans with some form of macular degeneration. [Bright Focus Foundation] If there is a surviving child for each of these individuals with macular degeneration, at a 45% rate of familial risk, about 5 million middle age Americans who are related to macular degeneration patients are at high risk and should undergo a dark adaptation test in middle age. Proven medical, laser or surgical treatment for the common form of macular degeneration (also known as dry macular degeneration) is lacking. Institute of Medicine 2015 Preventive measures such as diet and UV-blue filtering sunglasses may slow down the progress of the disease. At this point in time there is no effective treatment for the most common form of macular degeneration. This has researchers scrambling to test various oral drugs, eye drops and nutraceuticals in an attempt to head off the predicted explosion in the number of cases of macular degeneration over the coming decade. [Acta Pol Pharm 2014] The AREDs (Age Related Eye Disease) dietary supplement is reported to slow the progress of dry macular degeneration by 25% over 10 years. Even with antioxidant therapy the disease insidiously progresses. A recent troubling study showed that 2 of 4 genetic groups tested did not experience a favorable response with the Age Related Eye Disease (AREDS2) dietary supplement. Over $400 million of the AREDS formula is sold annually. [Ophthalmology Jan 2015] While there are many non-invasive vision tests, many are not specific for macular degeneration. Results with other vision tests may be confounded by other eye disorders such as cataracts, glaucoma or diabetes. The ADAPTDX test is better than 88+% specific for macular degeneration. [Investigative Ophthalmology 2014; Clinical Epidemiological Research 2014] Given that human subjects with the earliest form of dry macular degeneration are twice as likely to exhibit delayed adaptation to dim light following a bright flash of light, ADAPTDX test is the measure of choice. [Current Eye Research 2015] The pharmaceutical industry has proposed statin cholesterol-lowering drugs as a potential remedy for macular degeneration but statins were recently shown to be ineffective. [Ophthalmology 2015] Given that many common drugs prescribed for cardiovascular disease inhibit abnormal blood formation in animals, studies were launched with beta blockers, ACE inhibitors and other drugs to treat advanced-stage macular degeneration, but these pharmaceuticals also failed to confer any protective effect. [Retina 2015] The fast-progressive form of macular degeneration (also known as wet macular degeneration) involves leakage of fluid or hemorrhage and/or invasion of the visual center of the eyes by abnormal blood vessels in an attempt to restore circulation to the retina. Fortunately there is effective treatment for this form of the disease as medicines (Lucentis, Avastin, Eylea) injected directly into the eyes on a monthly basis inhibit invasion by abnormal blood vessels (called angiogenesis or neovascularization), sparing patients from legal blindness (20/200 vision). About 85% of patients with wet macular degeneration are successfully treated with these medicines. Previously Dr. Richer documented that this same oral nutraceutical (Longevinex) that provides herbal antioxidants (resveratrol, quercetin) along with vitamin D, a metal binder (IP6 phytate from rice bran) and DNA-repairing nucleotides (RNA), is in some cases able to rescue patients from impending legal blindness among patients who have the fast progressive form of macular degeneration and who had failed conventional treatment with injected drugs. [Nutrients 2014; US Patent pending] While plain resveratrol has been demonstrated to inhibit new blood vessel formation at the back of the animal eyes [Investigative Ophthalmology Visual Science April 2011], Longevinex; was selected for study because it is the only resveratrol supplement that has undergone toxicity testing [Food Chemistry Toxicology Sept 2013] and has been demonstrated to exert six-fold stronger biological action than plain resveratrol. [PLoS One Dec 23, 2016] While there are many brands of resveratrol supplements, none have been demonstrated to perform equally to Longevinex. For example, Longevinex produced a 40% greater increase in flow mediated dilatation (4.4% to 10.0%) than plain resveratrol (4.1 to 7.7%) in comparable human studies. Impaired flow mediated dilatation is a decline in the ability of the arteries to widen upon physical exertion or emotional stress, which is considered the first sign of arterial disease. [Nutrition Research Nov 2011; Nutrition Metabolism Cardiovascular Disease Nov 2011] Dr. Richer cautions patients with eye disease not to presume other resveratrol supplements will work equally well as the brand carefully selected for study at the Veterans Health Center. Any promising therapy would be long overdue. There are 1.75 million senior Americans that already know they have the disease but another 7 million seniors exhibit early signs (drusen deposits) at the back of the eyes and are at high risk for irreversible vision loss. According to an authoritative report, by the year 2020 an estimated 2.95 million Americans will have macular degeneration. [Archives Ophthalmology 2004] Worldwide, by the year 2020 more than 196 million people will be diagnosed with macular degeneration rising to 288 million by 2040. [Institute of Medicine 2015] The prevalence of macular degeneration is 0% at age 50 years, 2.5% at age 70 and 6% at age 80. [JAMA Ophthalmology April 2004] Typical age of diagnosis is in the mid 60s (65.8 years mean age). By age 75 years about 30% of senior adults exhibit some degree of macular degeneration. [Survey Ophthalmology2006 ] Most of the subjects in this study were ~80 years of age, which indicates subjects with AMD may never be too old to benefit from nutraceutical therapy. All of the subjects tested were taking prescription drugs such as antacids for heartburn or statin drugs for cholesterol. A pressing problem is that humanity doesn't have another decade to undergo belabored trials to scientifically prove dry macular degeneration therapies work. Researchers urge shortened study times and reduced number of subjects to speed along discovery. [Advances Experimental Biology Medicine 2016] Longevinex® petitioned the FDA for an abbreviated study four years ago but the petition was rejected by the FDA. [FDA Petition] At this time no dietary supplement (even Longevinex) can make a claim or infer it prevents, treats or cures any disease. Any inferences made by manufacturers of resveratrol pills that their products perform in a similar manner to the product tested in this study may be misleading to elderly patients with limited vision due to macular degeneration. Dr. Stuart Richer OD, PhD, is Director, Ocular Preventative Medicine-Eye Clinic, James A. Lovell Federal Health Care Center (veterans hospital) and Associate Professor, Family & Preventive Medicine, Rosalind Franklin University of Medicine & Science, North Chicago. Colleagues in the study were Lawrence Ulanski II, MD, Chief of Ophthalmology, University Illinois Eye & Ear Infirmary and Anish Bhandari, MSc, MS1, Chicago Medical School. None of the researchers report any personal commercial interest in the nutraceuticals or medical devices used in the study. Dr. Richer's laboratory is the recipient of funding from Longevinex for research studies.
News Article | May 23, 2017
BETHESDA, Md.--(BUSINESS WIRE)--BrainScope Company, Inc. today announced the results of a study spanning over six years demonstrating that sports-related concussions can be objectively assessed using BrainScope’s proprietary electroencephalography (EEG) based Brain Function Index (BFI). Published in the peer-reviewed Journal of Head Trauma Rehabilitation, the study entitled “The Use of an Electrophysiological Brain Function Index in the Evaluation of Concussed Athletes” was conducted at 14 colleges and high schools, and funded in part through an award received under the NFL-GE Head Health Challenge I. In the study, 354 male contact sports athletes, 110 of whom sustained a concussion, were evaluated with results demonstrating that concussive injury significantly affected brain function, which was reflected in the BFI of the concussed athletes. BrainScope’s BFI, derived from characteristics of brain electrical activity that most closely reflect the physiology of concussion, was found to show highly significant differences between concussed athletes at the time of injury compared with non-injured athletes. Furthermore, at both pre-season baseline and 45 days following the injury, concussed athletes and the non-injured control group exhibited equivalent BFI scores, suggesting that the BFI can potentially provide an objective marker of concussive injury and recovery over time. The Centers for Disease Control and Prevention estimates that there are up to 3.8 million sports and recreation related concussions in the United States each year. Further, a 2014 JAMA publication reported head injury related hospital emergency room (ER) visits have increased at eight times the rate of overall ER visits. The increase most likely reflects the significant public awareness and media focus on both the short and long term consequences of concussion. There is currently no gold standard for concussion, so current evaluation and diagnosis has relied on subjective reporting of symptoms. “The results of this study are important in demonstrating the potential role for an EEG-based biomarker to assist with more objective evaluation of concussed individuals. It can advance our assessment of these injured athletes well beyond the current symptom based assessments,” said first author M. Alison Brooks, MD, MPH, Associate Director of Sport Concussion and Nutrition Research, University of Wisconsin Division of Intercollegiate Athletics. Recent studies show that an early initial diagnosis of concussion is related to better long term outcomes and earlier recovery, stressing the need for more objective markers. “The Brain Function Index integrated into the clinical assessment of injured athletes can provide an objective measure of brain function. It contributes to a clinician’s early diagnosis of concussion and more informed immediate decisions about return to play,” said Leslie S. Prichep, Chief Scientific Officer of BrainScope and a Professor at NYU School of Medicine. “The substantially increased awareness of concussions nationwide by parents, universities and sports organizations calls for more objective and comprehensive capabilities which can be accessed right at the point of care,” stated Michael Singer, CEO of BrainScope. “This multi-year study shows that BrainScope’s BFI can provide important quantitative information about the status of brain function after head injury. This is an important finding particularly when concussions can contribute to debilitating and lingering post-concussion symptoms,” added Singer. The company is currently selling the FDA Cleared BrainScope One, which includes its proprietary BFI for use in mildly presenting closed head injured patients between the ages of 18-85 years and evaluated within 3 days of injury. In the 720 patient BrainScope One prospective validation trial which led to its September 2016 FDA Clearance (K161068 – cleared and registered as “Ahead 300”), the BFI was shown to have a significant relationship with severity of functional impairment in mild head injured patients. This newly published study, conducted using BrainScope’s Investigational devices and within a population that extended below 18 years of age, had longitudinal findings beyond the utility of the BrainScope One product cleared by the FDA. The results of this study suggest the potential future use of the BFI for longer term assessments and to track recovery from concussion. “We are pleased about the recent commercial launch of BrainScope One to aid in early identification, evaluation and near-term return-to-play decisions for college and professional athletes, and excited about the potential future use of the BFI to track recovery from concussion over the long term,” stated Singer. M. Alison Brooks, MD; Jeffrey J. Bazarian, MD; Leslie S. Prichep, PhD; Samanwoy Ghosh Dastidar, PhD; Thomas M. Talavage, PhD; William Barr, PhD “The Use of an Electrophysiological Brain Function Index in the Evaluation of Concussed Athletes” Journal of Head Trauma Rehabilitation, May 17, 2017, doi:10.1097/HTR.0000000000000328. BrainScope is a medical neurotechnology company that is developing a new generation of handheld, easy-to-use, non-invasive devices designed to aid medical professionals in rapidly and objectively assessing various neurological conditions, beginning with traumatic brain injury (TBI), including concussion. The company’s first product introduced in 2017, BrainScope One, uses EEG-based technology that is non-invasive for mildly presenting patients 18-85 years old and within 3 days after head injury. BrainScope One measures and interprets brain electrical activity and a patient’s neurocognitive function, creating a panel of objective data to help physicians make their clinical diagnosis. BrainScope’s technology platform integrates databases of thousands of brainwave recordings with advanced digital signal processing, sophisticated algorithms, miniaturized hardware and disposable headset sensors, which are all covered by an extensive intellectual property portfolio of over 100 issued and pending patents. BrainScope has received four FDA clearances and ISO 13485:2003 Certification. BrainScope has partnered with the U.S. Department of Defense for the development of its TBI assessment technology, and was named both an original recipient and final awardee of the GE-NFL Head Health Challenge I. BrainScope has also received significant funding from private investors to accelerate its development efforts, with backing from Revolution (created by AOL co-founder Steve Case), ZG Ventures, Maryland Venture Fund, Brain Trust Accelerator Fund, and Difference Capital. For more information, please visit www.brainscope.com.
News Article | December 13, 2016
LA JOLLA, CA - December 13, 2016 - Diet composition around the time of pregnancy may influence whether offspring become obese, according to a new study using animal models at The Scripps Research Institute (TSRI). "Your diet itself matters, not just whether you are gaining excess weight or developing gestational diabetes," said TSRI Associate Professor Eric Zorrilla, who led the study in collaboration with Tim R. Nagy of the University of Alabama at Birmingham and Barry E. Levin of the Veterans Affairs (VA) Medical Center of East Orange, New Jersey, and Rutgers University. In fact, the researchers found that giving females a typical American, or Western, diet appeared to set the next generation up for lifelong obesity issues. This work was published recently in the American Journal of Physiology and featured in APSselect, a collection of the best research papers from all journals published by the American Physiological Society. It's Not Just about Weight The researchers made this discovery by studying two lines of rats, one selectively bred to be obesity-resistant to a high-fat diet and one bred to be unusually vulnerable. Rats from each group were fed either a diet with the same overall fat, saturated fat, carbohydrate and protein levels as a typical Western diet, or a lower-fat, higher-grain control diet. The scientists found that female rats given a Western diet in the weeks leading up to pregnancy, during pregnancy and during nursing had offspring more prone to obesity at birth, during early adolescence and--many months later--through adulthood. This occurred even if the mothers themselves did not overeat and maintained a healthy weight, body fat and insulin status. Zorrilla said the results were surprising because, whereas previous studies had shown that overweight mothers were more likely to have overweight offspring, the new findings suggest that diet alone can make a difference independent of weight gain. The Western diet seemed to set in motion a metabolic "program" that lasted throughout the rat's life. Although these rats slimmed down during puberty and early adulthood, they still showed a lower basal metabolic rate (less energy expended at while rest) and higher food intake during that time, which led to a return of obesity in mid-adulthood. "What we found interesting was that you sometimes see the same thing in humans, when a kid goes through a growth spurt," said study first author Jen Frihauf, who recently completed her PhD through the University of California, San Diego, while working in the Zorrilla lab at TSRI. The researchers also spotted an interesting difference in the effects of the Western diet between the obesity-vulnerable and obesity-resistant lines: in females, the diet impaired the reproduction of the obesity vulnerable lines. Significantly fewer of females were able to reproduce, and those that did reproduce had fewer offspring. "This wasn't the focus of the study, but it supports the idea that a Western diet promotes infertility in mothers vulnerable to diet-induced obesity," said Zorrilla. The researchers also identified elevated levels of several molecules, such as insulin and hormones called leptin and adiponectin, starting at birth in both the Western diet and genetically vulnerable offspring. This hormone profile may serve as an early biomarker for detecting obesity risk. The Takeaway for Moms: Better Nutrition Research is ongoing into which aspects of a Western diet trigger these effects--and the molecular changes in the offspring responsible for them. Zorrilla said the findings should raise awareness of the importance of a healthy pre- and post-natal diet. For example, doctors may want to discuss nutrition with all women who are pregnant or are planning to become pregnant, not just those already overweight. "Doctors often use weight gain as a hallmark of a healthy pregnancy," said Frihauf. "But we realized there was something going on in utero that wasn't detectable in the mother's weight." Frihauf added that few pregnant women, even in the United States, eat a high-fat, high-sugar diet all day, every day. "We're not trying to tell pregnant women not to occasionally splurge on a piece of cake," she said. Studies have also shown that paternal diet, through "epigenetic" mechanisms that control how genes are expressed, can affect obesity risk in offspring, added Zorrilla, so nutritional information may be valuable for potential fathers as well. In addition to Zorrilla, Nagy, Levin and Frihauf, the study, "Maternal Western Diet Increases Adiposity Even in Male Offspring of Obesity-Resistant Rat Dams: Early Endocrine Risk Markers," was authored by Éva M. Fekete, previous of TSRI and now at The University of Wisconsin-Madison. This study was supported by the National Institutes of Health (grants R01DK-070118, R01DK-30066, R01DK-076896, F31DA026708-01A2, R21DK-077616, P30DK-056336 and P30DK-079626) and the Research Service of the VA. The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists--including two Nobel laureates and 20 members of the National Academy of Science, Engineering or Medicine--work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see http://www. .
Brunger L.,University of Sussex |
Smith A.,University of Sussex |
Re R.,Nutrition Research |
Wickham M.,Nutrition Research |
And 3 more authors.
Appetite | Year: 2015
The study aimed to validate appetite ratings made on a new electronic device, the Apple iPad Mini, against an existing but now obsolete electronic device (Hewlett Packard iPAQ). Healthy volunteers (9 men and 9 women) rated their appetite before and 0, 30, 60, 90 and 120 minutes after consuming both a low energy (LE: 77kcal) and high energy (HE: 274kcal) beverage at breakfast on 2 non-consecutive days in counter-balanced order. Rated hunger, desire to eat and how much participants could consume was significantly lower after HE than LE on both devices, although there was better overall differentiation between HE and LE for ratings on iPad. Rated satiation and fullness, and a composite measure combining all five ratings, was significantly higher after HE than LE on both devices. There was also evidence that differences between conditions were more significant when analysed at each time point than using an overall area under the curve (AUC) measure. Overall, these data confirm that appetite ratings made using iPad are at least as sensitive as those on iPAQ, and offer a new platform for researchers to collect appetite data. © 2014 Elsevier Ltd.
PubMed | World Sugar Research Organisation, University of Sussex and Nutrition Research
Type: Journal Article | Journal: International journal of obesity (2005) | Year: 2016
Consumption of high-energy beverages has been implicated as a risk factor for weight gain, yet why nutrients ingested as beverages fail to generate adequate satiety remains unclear. In general, consumers do not expect drinks to be satiating, but drinks generate greater satiety when their sensory characteristics imply they may be filling. These findings challenge traditional bottom-up models of how gut-based satiety signals modify behaviour to suggest that beliefs at the point of ingestion modify gut-based satiety signalling.Healthy volunteers (n=23) consumed four different beverages, combining an overt sensory manipulation (thin, low sensory (LS) or thicker and more creamy, enhanced sensory (ES)) and covert nutrient manipulation (low energy (LE), 78kcal; high energy (HE), 267kcal) on different days. Effects on satiety were assessed through rated appetite and levels of glucose, insulin, pancreatic polypeptide (PP) and cholesystokinin (CCK) recorded periodically over 90min, and through intake at an ad libitum test lunch.Intake at the test lunch and rated appetite were both altered by both the sensory and nutrient manipulations, with lowest intake and greatest suppression of hunger post-drink in the ESHE condition. Insulin increased more after HE than LE drinks, and after ES than LS drinks, whereas PP levels were higher after ES than LS versions. CCK levels only increased after the ESHE drink.These data confirm acute sensitivity of satiety after consuming a drink both to the sensory characteristics and nutrient content of the drink, and suggest that this may be, at least in part, due to top-down modulation of release of satiety-related gut hormones.
News Article | November 30, 2015
30th November: Fonterra today announced that commercial samples of NZMP Galacto-Oligosaccharides (GOS) will be available early in the new year. Fonterra’s new partnership with leading UK dairy company, Dairy Crest, means it can now offer the specialty paediatric ingredient to food manufacturers globally. NZMP GOS will give infant formula manufacturers the ability to offer additional consumer benefits. GOS is known to support digestive comfort  and improve mineral absorption . It’s anticipated that European and Chinese infant formula manufacturers will be among the first to start using NZMP GOS. Fonterra Regional Director Ingredients Europe Middle East/Africa Han Huistra says this innovative ingredient is an extension of the NZMP specialty ingredients portfolio for infant nutrition. “Combined with Fonterra’s expertise in paediatric nutrition, the ever growing portfolio of NZMP ingredients gives manufacturers even more flexibility to fine tune their products.” Mr Huistra says adding GOS to the NZMP portfolio means customers can benefit from Fonterra’s size, scale and ability to supply globally. “We are delighted to add this important ingredient to our portfolio of specialised NZMP ingredient offerings. A new facility brings the very real advantages of being able to capitalise on latest control systems and equipment to consistently produce high quality products. What makes this exciting is that traceability and supply versatility have also been designed as key traits for this business launch,” says Mr Huistra. Dairy Crest Managing Director Functional Ingredients Richard Jones says: “By leveraging our expertise in the manufacture of dairy products, and Fonterra’s global reach and supply capabilities, we are delighted to successfully deliver high quality nutritional products to meet growing market demands. It is a testament to the strong Fonterra-Dairy Crest partnership and our ability to meet the desire globally for quality nutrition.” Once production is running at full scale, Dairy Crest will manufacture 10,000 MT of GOS annually and the product will be marketed and sold under the NZMP brand utilising Fonterra’s global distribution network. NZMP GOS will be produced at Dairy Crest’s Davidstow facility in Cornwall, United Kingdom. Dairy Crest has invested £20 million to set up a purpose-built, state-of-the-art ingredients facility to produce GOS. “The heritage of excellence in dairy and quality manufacture makes Dairy Crest’s GOS facility investment a natural fit for Fonterra and our dairy ingredients brand, NZMP” says Mr Huistra.  Ashley, C. et al., 2012 Nutrition Journal 11, 38  Chonan, O and Watanuki, M., 1996. International Journal for Vitamin and Nutrition Research 66(3), 244-249. About GOS: Galacto-Oligosaccharides (GOS) are food ingredients with prebiotic properties, widely recognised to be bifidogenic, and to promote the growth of a host of beneficial gut bacteria in babies. GOS is derived from bovine milk, and recognised by many as a closer match to Human Milk Oligosaccharides compared to plant derived alternates. It is therefore the preferred pre-biotic for many infant formula brand owners. For further information contact: Christine Reilly, Hotwire PR on behalf of Fonterra phone: +44 (0)207 608 2500 About Fonterra Fonterra is a global leader in dairy nutrition – the preferred supplier of dairy ingredients to many of the world’s leading food companies. It is also a market leader with its own consumer dairy brands in New Zealand and Australia, Asia, Africa, the Middle East and Latin America. Fonterra is a farmer-owned co-operative and the largest processor of milk in the world. It is one of the world’s largest investors in dairy research and innovation drawing on generations of dairy expertise to produce more than two million tonnes of dairy ingredients, value added dairy ingredients, specialty ingredients and consumer products for 140 markets. About NZMP NZMP is the dairy ingredients brand of Fonterra. Trusted globally, NZMP ingredients are sold in more than 100 countries and can be found at the heart of some of the world’s most famous food and nutrition brands. NZMP has the broadest range of ingredients in the dairy industry, providing hundreds of solutions to meet the needs of customers every day. Backed by Fonterra’s global market expertise, world-class processing and leading quality standards, NZMP ingredients deliver real market advantage, trusted for their high performance and exceptional quality. About Dairy Crest Dairy Crest, home of the “Cathedral City” brand (no 1 UK consumer cheese brand) are the UK’s leading producer of quality cheese and whey. Their recent investment now aligns whey from their integrated milk pool into high quality infant formula ingredients. Together with technology partner Fayrefield, Dairy Crest is also leveraging their site manufacturing excellence to produce GOS.
News Article | March 2, 2017
Herbalife, a global nutrition company, today announced the launch of its first Nutrition Research and Development Labin India, in partnership with Syngene, Asia's leading contract research and manufacturing organization.
Pombo-Rodrigues S.,Nutrition Research |
Calame W.,StatistiCal BV |
Re R.,Nutrition Research
International Journal of Food Sciences and Nutrition | Year: 2011
The aim of the present work was to investigate the effects of eggs consumed for lunch on satiety, satiation and subsequent energy intake at the next meal. Thirty-one healthy male and female subjects participated in a randomized, three-way, crossover study. Following consumption of a standard breakfast, participants were asked to consume three isocaloric test lunches: omelette, jacket potato and chicken sandwich. Subjective measures of satiety were recorded using visual analog scales at regular intervals throughout the day. Energy intake at the next meal was assessed 4 h after lunch with an ad libitum meal. The egg lunch showed a significantly stronger satiating effect compared with the jacket potato meal. No effect on energy intake was seen. These data indicate that consumption of an omelette meal consumed at lunch could increase satiety to a greater extent than a carbohydrate meal and may facilitate reduction of energy consumption between meals. © 2011 Informa UK, Ltd.
Hull S.,Nutrition Research |
Re R.,Nutrition Research |
Tiihonen K.,DuPont Company |
Viscione L.,DuPont Company |
Wickham M.,Nutrition Research
Appetite | Year: 2012
Polydextrose (Litesse®, DuPont) is a polysaccharide that is partially fermented in the colon. Evidence suggests that polydextrose increases satiety when consumed over several weeks; however studies assessing its acute effects on satiety are lacking. This study therefore aimed to assess the impact of different doses of polydextrose on satiety and energy intake at subsequent meals during a test day. Three yogurt-based drinks containing different amounts of polydextrose (0, 6.25 and 12.5. g) were tested using a randomised, single-blinded, placebo controlled, cross-over design. Thirty-four healthy male and female volunteers were provided with a standard breakfast, then consumed the test product mid-morning, 90. min before an ad libitum lunch, which was followed by an ad libitum dinner. Visual analogue scales were used to measure subjective ratings of appetite, liking and discomfort. Consuming 6.25 and 12.5. g polydextrose increased satiety and decreased appetite compared to control immediately after consumption. A reduction in energy intake (218.8. kJ) at lunchtime was observed for 12.5. g polydextrose. This reduction in energy intake was not compensated for at dinner. This study suggests that polydextrose may aid in increasing satiety feelings post consumption and also reduce energy intake as a result. © 2012 Elsevier Ltd.
PubMed | Nutrition Research
Type: Journal Article | Journal: European journal of nutrition | Year: 2015
To assess the effect of consuming a mid-morning almond snack (28 and 42 g) tested against a negative control of no almonds on acute satiety responses.On three test days, 32 healthy females consumed a standard breakfast followed by 0, 28 or 42 g of almonds as a mid-morning snack and then ad libitum meals at lunch and dinner. The effect of the almond snacks on satiety was assessed by measuring energy intake (kcal) at the two ad libitum meals and subjective appetite ratings (visual analogue scales) throughout the test days.Intake at lunch and dinner significantly decreased in a dose-dependent manner in response to the almond snacks. Overall, a similar amount of energy was consumed on all three test days indicating that participants compensated for the 173 and 259 kcals consumed as almonds on the 28 and 42 g test days, respectively. Subjective appetite ratings in the interval between the mid-morning snack and lunch were consistent with dose-dependent enhanced satiety following the almond snacks. However, in the interval between lunch and dinner, appetite ratings were not dependent on the mid-morning snack.Almonds might be a healthy snack option since their acute satiating effects are likely to result in no net increase in energy consumed over a day.